Concentration effect modelling with converting enzyme inhibitors in man.
作者信息
Kelman A W, Reid J L, Millar J A
出版信息
Br J Clin Pharmacol. 1983 Apr;15(4):506-7. doi: 10.1111/j.1365-2125.1983.tb01542.x.
Abstract
摘要
相似文献
1
Concentration effect modelling with converting enzyme inhibitors in man.人体中转换酶抑制剂的浓度效应建模。
Br J Clin Pharmacol. 1983 Apr;15(4):506-7. doi: 10.1111/j.1365-2125.1983.tb01542.x.
2
3
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.正常志愿者中马来酸依那普利与赖氨酸类似物（MK-521）；血浆药物水平与肾素-血管紧张素系统之间的关系
Br J Clin Pharmacol. 1982 Sep;14(3):363-8. doi: 10.1111/j.1365-2125.1982.tb01992.x.
4
5
[Angiotensin-converting enzyme inhibitors as neutralizers of hydroxyl radical].[血管紧张素转换酶抑制剂作为羟自由基的中和剂]
Rev Port Cardiol. 1992 May;11(5):425-30.
6
Enalapril maleate and a lysine analogue (MK-521): disposition in man.马来酸依那普利与赖氨酸类似物（MK-521）：在人体中的处置情况
Br J Clin Pharmacol. 1982 Sep;14(3):357-62. doi: 10.1111/j.1365-2125.1982.tb01991.x.
7
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.转换酶抑制的药效学：MK421（依那普利）和MK521的心血管、内分泌及自主神经效应
Br J Clin Pharmacol. 1982 Sep;14(3):347-55. doi: 10.1111/j.1365-2125.1982.tb01990.x.
8
Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.血管紧张素转换酶抑制剂。其降压作用机制的差异。
Am J Hypertens. 1988 Jul;1(3 Pt 3):214S-216S. doi: 10.1093/ajh/1.3.214s.
9
Effects of enalapril, a new converting enzyme inhibitor, in hypertension.新型转换酶抑制剂依那普利对高血压的作用。
Clin Pharmacol Ther. 1982 Jul;32(1):48-53. doi: 10.1038/clpt.1982.125.
10
Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.依那普利和赖诺普利单独使用及与肼屈嗪联用的比较药代动力学
J Hum Hypertens. 1989 Jun;3 Suppl 1:147-51.
引用本文的文献
1
Pharmacokinetic-pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers.在血压正常的志愿者中，将扎西普利拉血浆浓度与肱动脉和股动脉血流动力学效应相关联的药代动力学-药效学模型。
Br J Clin Pharmacol. 1998 Oct;46(4):383-93. doi: 10.1046/j.1365-2125.1998.00786.x.
2
Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.一种新型口服活性血管紧张素转换酶抑制剂（HOE 498）在健康受试者中的药代动力学和药效学。
Eur J Clin Pharmacol. 1984;27(5):577-81. doi: 10.1007/BF00556895.
3
Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.年龄与血管紧张素转换酶抑制剂依那普利和依那普利拉的药代动力学
Br J Clin Pharmacol. 1986 Apr;21(4):341-8. doi: 10.1111/j.1365-2125.1986.tb05205.x.
4
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.血管紧张素转换酶抑制剂。药效学与药代动力学之间的关系。
Clin Pharmacokinet. 1988 Nov;15(5):295-318. doi: 10.2165/00003088-198815050-00003.
5
Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man.口服扎西普利（一种血管紧张素转换酶抑制剂）对血压正常男性的药效学、药代动力学及体液影响
Br J Clin Pharmacol. 1990 Jul;30(1):107-13. doi: 10.1111/j.1365-2125.1990.tb03749.x.
6
The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.喹那普利及喹那普利拉在肾功能损害患者中的药代动力学和药效学
Br J Clin Pharmacol. 1990 Aug;30(2):213-20. doi: 10.1111/j.1365-2125.1990.tb03767.x.
7
Steady-state pharmacokinetics and pharmacodynamics of benazeprilat in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats.
Pharm Res. 1991 Jul;8(7):883-7. doi: 10.1023/a:1015803529013.
8
Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.组织和血浆血管紧张素转换酶以及对血管紧张素转换酶抑制剂药物的反应。
Br J Clin Pharmacol. 1991 Jan;31(1):1-13. doi: 10.1111/j.1365-2125.1991.tb03851.x.
9
The description and prediction of antihypertensive drug response: an individualised approach.抗高血压药物反应的描述与预测：一种个体化方法。
Br J Clin Pharmacol. 1991 Jun;31(6):627-34. doi: 10.1111/j.1365-2125.1991.tb05584.x.
本文引用的文献
1
Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.卡托普利治疗：肾素、血管紧张素I和II、醛固酮及血压的剂间变化
Br J Clin Pharmacol. 1982 Jun;13(6):855-8. doi: 10.1111/j.1365-2125.1982.tb01878.x.
2
Disposition of captopril in normal subjects.卡托普利在正常受试者体内的处置情况。
Clin Pharmacol Ther. 1980 May;27(5):636-41. doi: 10.1038/clpt.1980.90.
3
Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.正常志愿者中马来酸依那普利与赖氨酸类似物（MK-521）；血浆药物水平与肾素-血管紧张素系统之间的关系
Br J Clin Pharmacol. 1982 Sep;14(3):363-8. doi: 10.1111/j.1365-2125.1982.tb01992.x.
4
Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.转换酶抑制的药效学：MK421（依那普利）和MK521的心血管、内分泌及自主神经效应
Br J Clin Pharmacol. 1982 Sep;14(3):347-55. doi: 10.1111/j.1365-2125.1982.tb01990.x.
5
Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.卡托普利对血管紧张素I转换酶“活性”和“浓度”的相反作用；酶抑制与长期血压反应之间的关系。
Clin Sci (Lond). 1981 May;60(5):491-8. doi: 10.1042/cs0600491.
6
The measurement of angiotensin-converting enzyme in subjects receiving captopril.接受卡托普利治疗的受试者体内血管紧张素转换酶的测定。
N Engl J Med. 1980 Aug 14;303(7):397. doi: 10.1056/NEJM198008143030717.
7
Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.卡托普利的降压效果与血管紧张素转换酶抑制作用之间的差异。
Hypertension. 1980 Mar-Apr;2(2):236-42. doi: 10.1161/01.hyp.2.2.236.
Zotero 插件